Safety and Efficacy of MLC601 in Iranian Patients after Stroke: A Double-Blind, Placebo-Controlled Clinical Trial

Objective. To investigate the safety and efficacy of MLC601 (NeuroAid) as a traditional Chinese medicine on motor recovery after ischemic stroke. Methods. This study was a double-blind, placebo-controlled clinical trial on 150 patients with a recent (less than 3 month) ischemic stroke. All patients were given either MLC601 (100 patients) or placebo (50 patients), 4 capsules 3 times a day, as an add-on to standard stroke treatment for 3 months. Results. Sex, age, elapsed time from stroke onset, and risk factors in the treatment group were not significantly different from placebo group at baseline (P > .05). Repeated measures analysis showed that Fugl-Meyer assessment was significantly higher in the treatment group during 12 weeks after stroke (P < .001). Good tolerability to treatment was shown, and adverse events were mild and transient. Conclusion. MLC601 showed better motor recovery than placebo and was safe on top of standard ischemic stroke medications especially in the severe and moderate cases.

[Atypical aspects of the electroencephalogram in subacute sclerosing panencephalitis]

Diffuse paroxysmal and periodic discharges in subacute sclerosing panencephalitis (SSPE), have a specific temporo-spatial character in about 90% of cases. A random selection of 100 among 358 cases was performed in this study and the following results were obtained. Twelve cases showed no initial diffuse paroxysmal and periodic discharges but an atypical pattern consisting in: 1) unilateral periodic activity (three cases); 2) bifrontal rhythmic delta activity (two cases); 3) epileptic discharges, one of which was absence (four cases); focal delta activity (one case); 5) normal EEG (two cases). One apparently benign case is also reported.